DJIA 17,959.44 154.64 0.87%
NASDAQ 4,781.42 16.04 0.34%
S&P 500 2,078.54 7.89 0.38%
market minute promo

ArQule, Inc. (NASDAQ: ARQL)



company name or ticker

Benzinga's Top #PreMarket Gainers

Why ArQule Inc. Shares Surged in After-Hours Trading

ArQule shares surge 26% after updating clinical trial data for key cancer drug tivantinib.

RedHill Biopharma Sells ADS - Analyst Blog

ArQule, Inc. Enters Oversold Territory - Tale of the Tape

ArQule, Inc. Enters Oversold Territory - Tale of the Tape

Narrower-than-Expected Loss at ArQule - Analyst Blog

ArQule Management Discusses Q3 2013 Results - Earnings Call Transcript

ArQule, Inc. Discusses Q3 2013 Results (Webcast)

ArQule Stock Sees Short Interest Increase 18%

Data on ArQule's Tivantinib - Analyst Blog

Four Unusual Stock Winners on a Down Friday

See More Articles...